Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01051661 | P3 |
Completed |
Influenza, Human |
2011-08-31 |
2020-05-14 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
| NCT00976820 | P2 |
Completed |
Influenza, Human |
2011-03-21 |
2019-03-19 |
Treatments |
|
| NCT00979602 | P3 |
Completed |
Influenza, Human |
2011-01-10 |
2019-03-19 |
Treatments |
|
| NCT00985673 | P2 |
Completed |
Influenza, Human |
2009-12-28 |
2019-03-19 |
Treatments |
|
| NCT00985088 | P2 |
Completed |
Influenza, Human |
2009-11-09 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|